Company Overview and News

16
Contrafect: A New Anti-Microbial Treatment Paradigm

2018-10-11 seekingalpha - 2
Bacteriophage, and their evolved weapons, have long been eyed as a means of controlling bacterial growth.
AKAO CFRX

14
Achaogen Announces Multiple Plazomicin Presentations at IDWeek 2018

2018-09-19 globenewswire
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing, and commercializing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced six upcoming presentations on plazomicin at the Infectious Diseases Society of America (IDSA) IDWeek™ 2018, being held in San Francisco, CA from October 3 to 7, 2018.
AKAO

14
Achaogen to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

2018-09-18 globenewswire
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that the Company will present a corporate overview at the 2018 Cantor Fitzgerald Global Healthcare Conference taking place October 1 to 3, 2018 in New York.
AKAO

35
AKAO / Achaogen, Inc. 8-K/A (Current Report)

2018-09-17 sec.gov - 21
8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AKAO

32
The Waiting Is The Hardest Part - The Idea Guide

2018-09-07 seekingalpha - 16
Stock ideas usually take time to play out, and the waiting can be the hard part.
TDOC W MFINL PSMT SLB CMCSA SLB AKAO MFIN FANH

24
Achaogen Is A Victim Of Unfortunate Circumstances

2018-09-05 seekingalpha - 10
Since the approval of Zemdri for UTI, shares in Achaogen have slipped considerably. We explore why this is.
AKAO

14
Achaogen Highlights Multiple Plazomicin Presentations at ESCMID/ASM 2018 Conference

2018-09-04 globenewswire
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today highlighted four poster presentations about plazomicin at the ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance that is being held from September 4 to 7, 2018 in Lisbon, Portugal.
AKAO

20
Achaogen Continues To Slide - How Much Farther Can It Go?

2018-08-27 seekingalpha - 6
Although Achaogen's lead drug candidate Zemdri received approval in June for the treatment of complicated urinary tract infections (cUTI), Achaogen's stock has trended strongly downwards since that time.
AKAO

27
Is the Options Market Predicting a Spike in Achaogen (AKAO) Stock?

2018-08-24 zacks - 3
Investors in Achaogen, Inc. (AKAO - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 21, 2018 $10 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
NWL AKAO

15
Our First Look At Spero Therapeutics

2018-08-21 seekingalpha - 1
Antibiotics concern Spero Therapeutics recently used a positive interim Phase 1 readout on its lead candidate (SPR994) as an opportunity to execute a secondary offering.
MDR AKAO

20
New Strong Sell Stocks for August 7th

2018-08-07 zacks - 2
Achaogen, Inc. (AKAO - Free Report) engages in discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Zacks Consensus Estimate for its current year earnings has been revised 3.3% downward over the last 30 days.
NXEOW RIO RIO MGR WYNN AMG REN NXEOU RTPPF SLRC AMT RIO RTNTF NXEO AKAO SLRA GTLS

22
Achaogen's (AKAO) CEO Blake Wise on Q2 2018 Results - Earnings Call Transcript

2018-08-07 seekingalpha - 3
Good day, everyone. And welcome to the Achaogen Incorporated Second Quarter 2018 Earnings Call. Today's call is being recorded. At this time, I'd like to turn the conference over to Gary Loeb, General Counsel. Please go ahead, sir.
CAH AKAO

17
Achaogen (AKAO) Reports Q2 Loss, Tops Revenue Estimates

2018-08-06 zacks - 2
Achaogen (AKAO - Free Report) just came out with a quarterly loss of $1.20 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to loss of $0.78 per share a year ago. These figures are adjusted for non-recurring items.
KRNT AMT AKAO BRKS GTLS

14
AKAO / Achaogen, Inc. 8-K (Current Report)

2018-08-06 sec.gov
akao-8k_20180806.htm UNITED STATES
AKAO

AKAO : Achaogen Stock Analysis and Research Report

2017-11-08 - Asif

Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterial treatments against multi-drug resistant (“MDR”) gram-negative infections. Achaogen is researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (“cUTI”), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (“CRE”). In 2013, the Centers for Disease Control and Prevention identified CRE as a “nightmare bacteria” and an immediate public health threat that requires “urgent and aggressive action” and in 2017 the World Health Organization identified CRE as a Global Priority 1 Pathogen: Critical Need for Research and Development of New Antibiotics. On December 12, 2016, the company announced positive data from its two Phase 3 clinical trials for plazomicin. The firs...

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 004449104